Cancer Chemotherapy

Classification

Alkylating: cyclophosphamide, ifosfamide, cisplatin/carboplatin/oxaliplatin(platinum, alkylator-like), busulfan. Antimetabolites: methotrexate(folate antagonist), 5-FU(pyrimidine), 6-MP(purine), cytarabine. Antitumour antibiotics: doxorubicin/daunorubicin(anthracyclines), bleomycin, dactinomycin. Mitotic spindle inhibitors: vincristine/vinblastine(vinca alkaloids), paclitaxel/docetaxel(taxanes). Topoisomerase inhibitors: etoposide(topo II), irinotecan/topotecan(topo I). Hormonal: tamoxifen, aromatase inhibitors, GnRH agonists(other topics). Targeted: TKIs(imatinib), mAbs(trastuzumab, rituximab), checkpoint inhibitors(pembrolizumab).

Cell Cycle Framework (organizing principle)

Cancer cells divide MORE frequently → most cytotoxic mechanisms preferentially damage ACTIVELY DIVIDING cells → SAME reason normal tissue toxicity hits the FASTEST-DIVIDING normal tissues(marrow, GI mucosa, hair follicles) — one principle explains the shared toxicity pattern, not separate per-drug list.

Cell-cycle-SPECIFIC(antimetabolites=S phase; vinca/taxanes=M phase): act only on actively-cycling cells, best vs rapidly-proliferating tumours, prolonged/repeated exposure needed. Cell-cycle-NONSPECIFIC(alkylators, antitumour antibiotics): damage regardless of phase(incl resting G0) → better vs slower-growing tumours, steeper dose-response(single larger dose more rational than divided).

Mechanism — Key Agents

Cyclophosphamide: covalent DNA cross-linking(guanine, interstrand) → blocks strand separation → cell-cycle-NONSPECIFIC. PRODRUG(hepatic CYP450 activation) — activation ALSO generates ACROLEIN(toxic byproduct) → haemorrhagic cystitis(bladder mucosal damage, excreted in urine) → MESNA binds/neutralizes acrolein in urinary tract = targeted antidote-like co-therapy, not generic support.

Cisplatin: DNA platination/cross-linking(alkylator-like mechanism, different chemical class). Defining toxicities: NEPHROTOXICITY(direct proximal tubular, needs aggressive IV HYDRATION before/during) + severe emetogenicity(MOST emetogenic agent, aggressive multi-class antiemetic prophylaxis per Antiemetics framework) + ototoxicity/peripheral neuropathy(cumulative).

Methotrexate: folate antagonist, high-affinity DHFR inhibition(IDENTICAL enzyme as trimethoprim, human isoform here — methotrexate lacks trimethoprim’s bacterial-selective affinity) → blocks tetrahydrofolate regen → halts purine/thymidine synthesis, S-PHASE specific. Leucovorin(folinic acid) RESCUE — bypasses blocked reductase step, allows HIGHER effective doses while rescuing normal cells(timed after MTX acts on faster tumour cells) — IDENTICAL rescue logic as trimethoprim toxicity, now oncology-stakes. Also used LOW-dose for RA/psoriasis(immunomodulatory, not cytotoxic at this dose).

5-FU: pyrimidine antimetabolite → active metabolites inhibit thymidylate synthase(distinct from methotrexate’s broader upstream block). SAME active-metabolite endpoint as flucytosine’s incidental host toxicity(Antifungal Drugs) — same cytotoxic drug, 2 different topics, 2 different generation routes.

Doxorubicin(anthracycline): DNA intercalation(distorts helix, blocks transcription/replication) + topoisomerase II inhibition + generates ROS via redox cycling. ROS mechanism SPECIFICALLY responsible for CARDIOTOXICITY(cardiac tissue’s low antioxidant defence → disproportionate ROS vulnerability) — cumulative-dose-related, acute/reversible OR delayed/chronic IRREVERSIBLE(dilated cardiomyopathy). Dexrazoxane(iron chelator, ↓iron-catalyzed radical generation) = cardioprotective co-therapy near cumulative-dose threshold.

Vincristine/vinblastine: bind TUBULIN → inhibit polymerization(no spindle formation, metaphase arrest). Vincristine defining toxicity = PERIPHERAL NEUROPATHY(NOT marrow-dominant, unusual — microtubules essential for axonal transport, neurons specifically vulnerable). Vinblastine: MORE myelosuppression, LESS neuropathy than vincristine — agent-specific distinction within same class.

Paclitaxel(taxane): also binds tubulin, OPPOSITE mechanism — STABILIZES microtubules(prevents depolymerization, vs vinca preventing polymerization) — equally lethal to mitosis(static over-stabilized = as dysfunctional as can’t-form-at-all) — important contrast, both disrupt microtubule DYNAMICS in opposite directions.

Adverse Effects — Shared vs Class-Specific

Myelosuppression = dominant SHARED toxicity(rapidly-dividing-cell logic) — neutropenia(±G-CSF, Blood topic), anaemia, thrombocytopenia, nadir 7-14 days post-cycle. GI mucositis+alopecia = similarly shared(rapidly-dividing tissue). Emetogenicity varies by agent(cisplatin highest) — connects to CINV framework(Antiemetics).

Clinical Relevance

Shared rapidly-dividing-tissue vulnerability = ONE principle explaining entire chemo AE profile, not separate list per drug. Each agent’s DISTINGUISHING toxicity(doxorubicin=cardiotoxicity/ROS; vincristine=neuropathy/axonal transport; cisplatin=nephrotoxicity/tubular damage; cyclophosphamide=haemorrhagic cystitis/acrolein) = SEPARATE agent-specific mechanism layered on shared marrow/mucosal toxicity — recognizing “shared” vs “agent-specific” toxicity = what’s actually being tested re: dose-limiting toxicity questions.

Classification (by Mechanism)

Alkylating agents: cyclophosphamide, ifosfamide, cisplatin/carboplatin/oxaliplatin (platinum compounds, mechanistically alkylator-like), busulfan
Antimetabolites: methotrexate (folate antagonist), 5-fluorouracil (pyrimidine antagonist), 6-mercaptopurine (purine antagonist), cytarabine
Antitumour antibiotics: doxorubicin/daunorubicin (anthracyclines), bleomycin, dactinomycin
Mitotic spindle inhibitors: vincristine/vinblastine (vinca alkaloids), paclitaxel/docetaxel (taxanes)
Topoisomerase inhibitors: etoposide (topoisomerase II), irinotecan/topotecan (topoisomerase I)
Hormonal agents: tamoxifen, aromatase inhibitors, GnRH agonists (already covered under Gonadal Hormones and Related Drugs, and Pituitary Hormones respectively)
Targeted/biologic agents: tyrosine kinase inhibitors (imatinib), monoclonal antibodies (trastuzumab, rituximab), checkpoint inhibitors (pembrolizumab)

The Cell Cycle Framework

Nearly every classical (non-targeted) cytotoxic agent’s selectivity for cancer cells rests on one core principle: cancer cells divide more frequently than most normal cells, and most cytotoxic mechanisms preferentially damage actively dividing cells — this is also precisely why the normal tissues with the highest chemotherapy toxicity burden are exactly the normal tissues that also divide rapidly (bone marrow, GI mucosa, hair follicles), the organizing explanation for the shared toxicity pattern across nearly this entire drug class rather than an unrelated list of side effects per drug.

Cell-cycle-specific agents act only on cells actively cycling through a specific phase (antimetabolites — S phase; vinca alkaloids/taxanes — M phase) and are most effective against rapidly-proliferating tumours, generally given as prolonged or repeated exposure to catch cells as they cycle through the vulnerable phase. Cell-cycle-nonspecific agents (alkylating agents, antitumour antibiotics) damage cells regardless of cycle phase (including resting, G0 cells), generally more effective against slower-growing tumours and often exhibiting a steeper dose-response relationship, making single larger doses more rational than the same total dose divided.

Mechanism of Action — Key Classes

Alkylating agents (cyclophosphamide): form covalent bonds with DNA (classically cross-linking guanine bases, particularly interstrand cross-links between the two DNA strands), preventing strand separation during replication and causing lethal DNA damage — cell-cycle-nonspecific. Cyclophosphamide is a prodrug, requiring hepatic CYP450 activation to its active alkylating metabolites, and this activation pathway also generates acrolein, a toxic byproduct responsible for haemorrhagic cystitis (bladder mucosal damage from acrolein excreted in urine) — the specific, mechanism-driven reason mesna (which binds and neutralizes acrolein in the urinary tract) is co-administered with cyclophosphamide/ifosfamide specifically to prevent this toxicity, a genuinely targeted antidote-like co-therapy rather than a generic supportive measure.

Cisplatin: forms similar DNA cross-links via platination of DNA bases (mechanistically alkylator-like despite a different chemical class) — its defining, most clinically significant toxicity is nephrotoxicity (direct proximal tubular damage, requiring aggressive IV hydration before/during administration specifically to reduce this risk) and severe emetogenicity (among the most emetogenic chemotherapy agents, requiring aggressive multi-class antiemetic prophylaxis per the CINV framework already covered under Antiemetics) and ototoxicity/peripheral neuropathy (cumulative, dose-related).

Methotrexate: a folate antagonist, competitively and with very high affinity inhibiting dihydrofolate reductase (the identical enzyme trimethoprim inhibits under Sulfonamides and Cotrimoxazole, here targeting the human isoform rather than a bacterial one, given methotrexate lacks trimethoprim’s bacterial-selective affinity difference) — blocking tetrahydrofolate regeneration halts purine and thymidine synthesis, arresting DNA replication, primarily S-phase specific. Leucovorin (folinic acid) rescue — administering already-reduced folate that bypasses the blocked reductase step — allows genuinely higher, more effective methotrexate doses to be used while rescuing normal host cells from lethal antifolate toxicity, timed to be given after methotrexate has had time to act preferentially on the faster-dividing tumour cells, the identical folinic-acid-rescue logic already introduced for trimethoprim toxicity under Sulfonamides and Cotrimoxazole, here applied at oncology-relevant doses and stakes. Methotrexate is also used at much lower, non-oncologic doses for rheumatoid arthritis and psoriasis (an immunomodulatory rather than primarily cytotoxic use at this dose range).

5-Fluorouracil: a pyrimidine antimetabolite, converted intracellularly to active metabolites that inhibit thymidylate synthase (blocking thymidine synthesis specifically, distinct from methotrexate’s broader block further upstream in folate metabolism) — the same active-metabolite endpoint already referenced under Antifungal Drugs’ explanation of flucytosine’s incidental host toxicity (flucytosine’s minor bacterial-mediated conversion to 5-FU), worth recognizing as the same cytotoxic drug appearing in two entirely different topics via two different routes of generation.

Doxorubicin (anthracycline): intercalates directly into DNA (inserting between base pairs, distorting the helix and blocking transcription/replication) and inhibits topoisomerase II, and additionally generates reactive oxygen species via redox cycling — this last mechanism is specifically responsible for doxorubicin’s defining, dose-limiting cardiotoxicity (cardiac tissue’s comparatively lower antioxidant defence capacity makes it disproportionately vulnerable to ROS-mediated damage), which is cumulative-dose-related and can be either acute/reversible or, more concerningly, delayed/chronic and irreversible (a genuine dilated cardiomyopathy) — dexrazoxane (an iron-chelating agent, reducing iron-catalyzed free radical generation) is a specific, examined cardioprotective co-therapy used when cumulative doxorubicin dose approaches the cardiotoxicity threshold.

Vincristine/vinblastine (vinca alkaloids): bind tubulin, inhibiting microtubule polymerization (preventing mitotic spindle formation, arresting cells in metaphase — the mechanistic opposite of the taxanes below despite both targeting the same cytoskeletal protein) — vincristine’s defining, dose-limiting toxicity is peripheral neuropathy (rather than bone marrow suppression, unusually for a cytotoxic agent — microtubules are also essential for normal axonal transport, so neurons are specifically vulnerable to this particular mechanism), a specific, examined point distinguishing vincristine’s dose-limiting toxicity from most other chemotherapy classes’ marrow-dominant toxicity profile. Vinblastine, by contrast, causes more myelosuppression and comparatively less neuropathy than vincristine, a specific agent-to-agent distinction within the same drug class worth knowing.

Paclitaxel (taxane): also binds tubulin, but by the opposite mechanism from vinca alkaloids — stabilizing microtubules and preventing their normal depolymerization (rather than preventing polymerization), which is equally lethal to mitotic spindle function despite being mechanistically opposite (a static, over-stabilized microtubule is as dysfunctional for mitosis as one that can’t form at all) — a genuinely important, frequently-examined contrast worth stating explicitly (both classes disrupt microtubule dynamics, but in opposite directions).

Adverse Effects — Shared and Class-Specific

Myelosuppression is the dominant, shared toxicity across most cytotoxic classes (per the rapidly-dividing-cell-vulnerability logic above) — neutropenia (infection risk, sometimes managed with G-CSF, already covered under Blood), anaemia, and thrombocytopenia, generally nadir-timed 7–14 days after a treatment cycle with recovery before the next cycle in a standard regimen.

GI mucositis and alopecia are similarly shared, rapidly-dividing-tissue-driven toxicities across most classes.

Emetogenicity varies substantially by agent (cisplatin highest, requiring the most aggressive prophylaxis) — directly connecting back to the CINV mechanism/management framework under Antiemetics.

Clinical Relevance

The shared vulnerability of rapidly-dividing normal tissue is what makes the entire chemotherapy adverse-effect profile predictable from one underlying principle rather than a separate list per drug, while each individual agent’s distinguishing toxicity (doxorubicin’s cardiotoxicity from ROS generation, vincristine’s neuropathy from microtubule-dependent axonal transport, cisplatin’s nephrotoxicity from direct tubular damage, cyclophosphamide’s haemorrhagic cystitis from its acrolein byproduct) traces to a genuinely separate, agent-specific mechanism layered on top of the shared marrow/mucosal toxicity — recognizing which toxicity is “the shared one” versus “the agent-specific one” is what the exam is actually testing when it asks about a specific drug’s dose-limiting toxicity.

Cell cycle with each drug class’s phase of action marked (S-phase antimetabolites, M-phase spindle inhibitors, cycle-nonspecific alkylators).
Vinca alkaloid vs taxane opposite tubulin mechanisms (prevents polymerization vs prevents depolymerization) shown side by side.
Cyclophosphamide activation pathway generating both active alkylator and acrolein byproduct, with mesna’s neutralization point marked.